Abstract: PUB528
Comparison of Anti-human T-lymphocyte Immunoglobulin (r-ATLG) vs. Anti-thymocyte Globulin (r-ATG) as Induction Agents in Kidney Transplantation: A 5-Year Retrospective, Single-Center, Observational Study
Session Information
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- Sinha, Vijay Kumar, Jaypee Hospital, Noida, Uttar Pradesh, India
- Devra, Amit, Jaypee Hospital, Noida, Uttar Pradesh, India
- Singh, Ravi Kumar, Jaypee Hospital, Noida, Uttar Pradesh, India
- Pandey, Prashant, Jaypee Hospital, Noida, Uttar Pradesh, India
Background
T cell depletion agents, Anti-Thymocyte Globulin (r-ATG) and Anti-Human T-Lymphocyte Immunoglobulin (r-ATLG), are routinely employed as induction therapies in kidney transplantation. This study systematically evaluates the short-term and long-term outcomes of kidney transplants at our center, focusing on the comparative efficacy and safety profiles of these agents.
Methods
This retrospective cohort study analyzed data from kidney transplant recipients treated at a tertiary care hospital in India between 2017 and 2024. A total of 603 patients were included, with 381 receiving ATG and 222 receiving ATLG as induction therapy. All patients were maintained on a standard regimen of triple immunosuppressive therapy. Follow-up assessments included evaluations for graft rejection, infections, development of de novo diseases, and overall graft survival
Results
The mean follow-up duration was 60 months. The mean doses administered were 5.4 ± 1.4 mg/kg for ATLG and 2.37 ± 1.2 mg/kg for ATG. Baseline demographic and clinical characteristics were well-matched between the two groups. HLA matching showed <3/6 in 95 patients (42.7%) with ATLG and in 318 patients (83.4%) with ATG, while >3/6 HLA matching was found in 127 patients (57.2%) with ATLG and 63 patients (16.5%) with ATG. Serum creatinine levels at discharge and during follow-up intervals were comparable between groups. The incidence of de novo diseases was higher in the ATG group (12 cases, 3.1%) compared to the ATLG group (3 cases, 1.3%). However, the incidence of infections was similar between the two groups.
Conclusion
Both ATG and ATLG demonstrated similar efficacy in terms of short-term and long-term graft rejection rates in kidney transplant recipients.
Rejection Analysis between (ATLG and ATG)